Compare STEM & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | PYXS |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 82.3M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | PYXS |
|---|---|---|
| Price | $9.42 | $1.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $13.33 | $7.00 |
| AVG Volume (30 Days) | 107.0K | ★ 303.0K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $13,858,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $13.92 | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $0.29 | $0.87 |
| 52 Week High | $32.23 | $5.55 |
| Indicator | STEM | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 63.21 |
| Support Level | $8.12 | $1.28 |
| Resistance Level | $10.99 | $2.17 |
| Average True Range (ATR) | 0.71 | 0.11 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 48.43 | 97.78 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.